
05/16/2025
๐ ๐จ๐ฆ Transforming Cancer Treatment: Guardant Health's Precision Oncology Tests Now Available at Bayshore Clinics! ๐จ๐ฆ ๐
Guardant Health, a leading precision oncology company, announced on April 3, 2025, that it has entered into an agreement with Bayshore HealthCare, a prominent home and community healthcare service provider in Canada. This partnership aims to offer Guardantโs portfolio of precision oncology tests across Bayshore's network of clinics in Canada, excluding Quebec. Bayshore HealthCare, which provides care to over 350,000 Canadians annually, will now offer advanced cancer testing tools, including the Guardant360ยฎ test for therapy selection in advanced cancer, the Guardant Revealโข blood test for minimal residual disease (MRD) detection and recurrence monitoring in early-stage cancer, and the Shieldโข blood test for colorectal cancer screening.
โ
Helmy Eltoukhy, Guardant chairman and co-CEO, expressed pride in partnering with Bayshore HealthCare, emphasizing that this collaboration will provide physicians with the latest molecular profiling technology to develop personalized care plans, improve patient outcomes, and reduce cancer-related mortality. Karl Frank, Divisional Director of Bayshore Specialty Rx, highlighted that this partnership aligns with Bayshore's mission to provide customized care plans, enabling healthcare providers to detect cancer earlier, develop targeted treatment programs, and better monitor patient responses to therapy.
โ
Don't miss out on this groundbreaking partnership between Guardant Health and Bayshore HealthCare! Stay informed about the latest advancements in cancer care and how they can benefit you and your loved ones. Together, we can make a difference in the fight against cancer!